|
業務類別
|
Biotechnology |
|
業務概覽
|
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes. |
| 公司地址
| 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 619 876-0700 |
| 傳真號碼
| -- |
| 公司網頁
| |
| 員工數量
| -- |
| Mr. Brendan R. Winslow |
Chief Financial Officer |
-- |
27/02/2026 |
| Ms. Stephanie Kenney |
Chief Corporate Affairs Officer |
-- |
17/02/2026 |
| Ms. Kathleen P. Gallagher |
Director, President and Chief Executive Officer |
-- |
27/02/2026 |
| Dr. Steven George Hughes, M.D. |
Chief Medical Officer |
-- |
17/02/2026 |
| Mr. Rocio Martin Hoyos |
Chief Strategy Officer |
-- |
17/02/2026 |
| Dr. Husam Younis, PhD |
Chief Scientific Officer |
-- |
17/02/2026 |
|
|
| Ms. Simona Skerjanec, M.B.A. |
Independent Director |
27/02/2026 |
| Dr. W. Michael Flanagan, PhD |
Independent Director |
27/02/2026 |
| Ms. Kathleen P. Gallagher |
Director, President and Chief Executive Officer |
27/02/2026 |
| Mr. Carsten Boess |
Independent Director |
27/02/2026 |
| Dr. Troy E. Wilson, PhD, J.D. |
Independent Director |
27/02/2026 |
| Ms. Sarah Boyce |
Independent Director |
17/02/2026 |
|
|
|
|
